Core Viewpoint - Liberty Gold Corp. has appointed Brad Ralph as Senior Vice President of Corporate Development, bringing over twenty years of experience in corporate development and investment banking, particularly in the mining sector [1][2]. Company Overview - Liberty Gold is focused on developing open pit oxide deposits in the Great Basin of the United States, which is known for its large-scale gold projects suitable for open-pit mining [4]. - The company is advancing the Black Pine Project in southeastern Idaho, which is a past-producing, Carlin-style gold system with significant resource potential and strong economic viability [4]. Executive Profile - Brad Ralph has a robust background in corporate development and investment banking, having served as CEO of Accelera Capital Inc. and held senior roles at various financial institutions [2][3]. - His expertise includes managing acquisition and sale transactions, sourcing funding solutions, and leading due diligence processes, with a notable track record in public markets and equity financing [3]. Leadership Statement - Jon Gilligan, President and CEO of Liberty Gold, expressed enthusiasm about Brad Ralph's appointment, highlighting his extensive experience in M&A transactions and project financing as critical for the company's growth [4].

Core Points - Pasinex Resources Limited has announced significant corporate developments, including the acquisition of the Sarıkaya zinc project, a change in financial year-end, updates on board nominations, progress on private placement financing, and the granting of stock options [1] Acquisition of Sarıkaya Zinc Project - The acquisition of the Sarıkaya zinc project in Türkiye has been completed, with Pasinex Arama now holding all outstanding shares of Aydın Teknik. The project features 30%-50% high-grade, carbonate-hosted zinc mineralization and is located near the Pinargozu mine [2] - The acquisition consolidates Pasinex's operations in Türkiye, as it now controls 100% of both the Pinargozu and Sarıkaya projects [2] Change in Financial Year-End - The company has changed its financial year-end from December 31 to March 31 to align its reporting cycle with industry peers. A transitional report will cover a fifteen-month period from January 1, 2025, to March 31, 2026 [3] Board Nomination and AGM - Dr. Mehmet Kömürcü has been nominated for election to the Board at the upcoming Annual General Meeting (AGM). He brings extensive experience in corporate governance and mining [4] - The AGM is scheduled for November 21, 2025, with a record date for voting set as October 17, 2025 [5] Private Placement Financing Update - The company has received strong investor support for its private placement financing, with over CAD $1.2 million in subscriptions out of a CAD $2.15 million offering. The financing is expected to close soon [6] Grant of Stock Options - Pasinex has granted 2,500,000 stock options to directors, officers, and key employees, which vest immediately and are exercisable at $0.075 per share [7] Management Comment - The Executive Chairman highlighted the transformative nature of recent developments, emphasizing the strategic control over two zinc projects and the positive outlook for growth and exploration [9]

Core Viewpoint - Cboe Global Markets has appointed Prashant Bhatia as Executive Vice President, Head of Enterprise Strategy & Corporate Development, effective September 2, 2025, to enhance its growth strategy and industry leadership [1][2]. Group 1: Appointment Details - Prashant Bhatia will collaborate with Cboe's executive leadership to refine the company's business strategy and identify growth opportunities [2]. - Craig Donohue, CEO of Cboe, emphasized Bhatia's valuable addition to the leadership team, highlighting his understanding of the competitive landscape and financial decision-making skills [2][3]. Group 2: Background of Prashant Bhatia - Bhatia has over 30 years of experience in the financial services sector, previously leading Enterprise Strategy & Corporate Development at TD Ameritrade for 11 years [3]. - He has been advising Cboe's management and working closely with its board of directors since December 2023 [3]. Group 3: Company Overview - Cboe Global Markets is recognized as the world's leading derivatives and securities exchange network, providing trading solutions across multiple asset classes globally [4]. - The company is committed to building a trusted and inclusive global marketplace to support sustainable financial futures [4].

Core Insights - Celestica Inc. has appointed Chris Colpitts to its Board of Directors, enhancing its leadership team as it continues to grow [1][3] - Mr. Colpitts brings 20 years of experience in technology, media, and telecommunications, with a strong background in investment banking and private equity [2] - The Board of Directors will now consist of 9 members following this appointment [4] Company Overview - Celestica is a leader in design, manufacturing, hardware platform, and supply chain solutions, partnering with top brands across various sectors including Aerospace and Defense, Communications, and HealthTech [5] - The company focuses on delivering solutions for complex challenges, leveraging global expertise throughout the product development process [5]

Core Insights - THOR Industries, Inc. has appointed Seth Woolf as Head of Corporate Development & Investor Relations, aiming to enhance long-term corporate initiatives and capital markets communications [1][2] - Woolf brings over 15 years of investment industry experience, particularly in the recreational vehicle sector, which will aid THOR in navigating market dynamics and supporting growth [2] Company Overview - THOR Industries is the largest manufacturer of recreational vehicles globally, owning several operating subsidiaries [3]

Financial Data and Key Metrics Changes - Jazz Pharmaceuticals reported total revenues of $898 million for Q1 2025, reflecting a solid commercial performance despite some headwinds in oncology products [6][26][27] - Revenues from the neuroscience portfolio, particularly Xywav and Epidiolex, grew by 9% and 10% year over year, respectively [6][12][14] - Oncology product sales decreased by 8% year over year, primarily due to changes in pediatric treatment protocols and one fewer shipping week compared to the previous year [15][27] Business Line Data and Key Metrics Changes - The sleep therapeutic area generated approximately $431 million in total revenue, with Xywav net product sales at approximately $345 million, marking a 9% increase year over year [10] - Epidiolex had net product sales of approximately $218 million, a 10% increase year over year, driven by underlying demand and favorable U.S. payer mix [12][14] - Oncology net product sales were approximately $94 million, down 8% year over year, with expectations for normalization in the coming quarters [15][27] Market Data and Key Metrics Changes - Xywav remains the number one branded treatment for narcolepsy, with approximately 14,600 active patients, reflecting a robust quarter of patient additions [10] - The idiopathic hypersomnia market is showing significant growth, with a 39% increase in patient adds over the last twelve months [84] - The company anticipates three potential regulatory approvals in oncology in the coming months, which could drive future growth [7][8] Company Strategy and Development Direction - The acquisition of Chimerix is expected to enhance Jazz's presence in rare oncology and provide a near-term commercial opportunity with doravaprone [6][24] - The company is focused on advancing its R&D pipeline, with key trials and data presentations expected at ASCO in June [8][19] - Jazz Pharmaceuticals aims to maintain financial flexibility and operational excellence while navigating potential tariff impacts [9][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the top-line revenue guidance for 2025, affirming a range of $4.15 billion to $4.4 billion, representing 5% year-over-year growth at the midpoint [33] - The company remains optimistic about the growth potential of Epidiolex and Xywav, with expectations for Epidiolex to reach blockbuster status in 2025 [14][34] - Management highlighted the importance of corporate development as a key strategy for long-term shareholder value [62] Other Important Information - The company updated its financial guidance to reflect the Chimerix acquisition and litigation settlement charges, impacting adjusted net income and earnings per share [28][33] - Jazz Pharmaceuticals has sufficient inventory in the U.S. to meet its 2025 needs, mitigating potential tariff impacts [30][29] Q&A Session Summary Question: Can you discuss the supply chain for Xywav and its U.S. manufacturing capabilities? - Management confirmed that they have a U.S. supplier for oxybate, including Xywav, with sufficient capacity to meet U.S. needs [42] Question: What is Jazz's manufacturing footprint and potential mitigation strategies for tariffs? - The company has manufacturing facilities in the U.S. and Europe, providing flexibility in sourcing and production [46] Question: How does the Chimerix acquisition fit into Jazz's strategy? - The acquisition aligns with Jazz's focus on addressing unmet medical needs in oncology and provides a near-term commercial opportunity [62] Question: What are the expectations for Zepzelca's growth trajectory amid competition? - Management anticipates that the first-line contribution will outweigh pressure from competitors, with upcoming data expected to be practice-changing [51][54] Question: What is the status of the doravaprone trial and its potential impact? - The FDA review is proceeding as expected, with no surprises, and the company is evaluating potential changes to the trial analysis plan [80]